ZEALAND PHARMA A/S: Financial statements 2022
CVR: 20045078
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2022. In 2022, the company reported revenue of EUR 103,986,000 and a net result of EUR -1,202,135,000 compared with DKK -1,018,149,000 the year before. That is a decrease of 64.5% compared with the year before. The profit margin was -1,156.1%. Equity in the 2022 report amounted to EUR 815,911,000. The solvency ratio was 53%. The company had 247 employees in the financial year.
- Revenue
- EUR 103,986,000
- Gross Profit
- EUR 103,986,000
- Profit/Loss
- EUR -1,202,135,000
- Equity
- EUR 815,911,000
- Total Assets
- EUR 1,539,806,000
- Employees
- 247
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 104M EUR | 104M EUR | -1.2B EUR | 815.9M EUR | 247 |
| 2021 | 292.6M | 173.8M | -1B | 927.8M | 346 |
| 2020 | 353.3M | 262.7M | -846.7M | 1.2B | 297 |
| 2019 | 41.3M | - | -571.5M | 1.2B | - |
| 2018 | 38M | - | 581.3M | 1.1B | - |
Official annual report
Keep an eye on ZEALAND PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2022 to September 30, 2022.
As of November 1, 2022, Henriette Wennicke is registered as director of ZEALAND PHARMA A/S.
As of August 31, 2022, Matthew Donald Dallas has stepped down as director of ZEALAND PHARMA A/S.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2022 to March 31, 2022.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2022 to June 30, 2022.
ZEALAND PHARMA A/S has published its annual report for 2021. Revenue came to DKK 292,567,000, and the net result was DKK -1,018,149,000.
As of March 30, 2022, Adam Sinding Steensberg is registered as adm. dir. of ZEALAND PHARMA A/S.
As of March 30, 2022, Emmanuel Dulac has stepped down as adm. dir. of ZEALAND PHARMA A/S.
As of March 29, 2022, Adam Sinding Steensberg has stepped down as director of ZEALAND PHARMA A/S.
About ZEALAND PHARMA A/S
ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.
